BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers

Stock Information for BioStem Technologies Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioStem Technologies Inc

BioStem Technologies Announces Extension to File 2024 Annual Report with OTC
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
BioStem Technologies CEO to Present at Biotech Showcase 2025
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.